1300590-75-3

Upstream product

• 1300590-73-1 C₃₃H₃₃N₃O₇ 
• 1300589-88-1 C₂₅H₂₅N₃O₆ 
• 1300589-85-8 C₂₅H₂₇N₃O₇ 
• 1300589-82-5 C₂₅H₂₅N₅O₇ 
• 1300589-79-0 C₂₅H₂₇N₅O₆ 
• 1300589-77-8 C₄₁H₄₅N₅O₆Si 
• 1300589-73-4 C₄₂H₄₅F₃N₂O₉SSi 
• 1300589-67-6 C₄₁H₄₄N₂O₆Si 
• 1300589-65-4 3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-5-methyluridine 
• 1300589-63-2 2'-O-acetyl-3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-5-methyluridine 
• 1300589-59-6 C₄₀H₄₆O₈Si 
• 153186-10-8 ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 74-88-4 methyl iodide 

Downstream Products

• 1300590-79-7 C₃₃H₃₃N₃O₈ 
• 1300590-81-1 N₂'-methyl-2'-amino-3'-O-[2-cyanoethoxy(diisopropylamino)phosphino]-5'-O-dimethoxytrityl-2'-N,4'-C-oxomethylene thymidine 

Relevant academic research and scientific papers

Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo

High scalability of a novel bicyclic nucleoside building block, amido-bridged nucleic acid (AmNA), to diversify pharmacokinetic properties of therapeutic antisense oligonucleotides is described. N2′-functionalization of AmNA with a variety of hydrophobic groups is straightforward. Combinations of these modules display similar antisense knockdown effects and improve cellular uptake, relative to sequence-matched conventional 2′,4′-bridged nucleic acid (2′,4′-BNA) in vivo. This journal is

BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE

It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity